MBX Biosciences (MBX) Other financing activities (2024 - 2026)

MBX Biosciences has disclosed Other financing activities across 3 years of filings, most recently posting $378000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $378000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 71.67% YoY), and the FY2025 annual result was $771000.0, down 81.02% from the prior year.
• Other financing activities came in at $378000.0 for Q1 2026 at MBX Biosciences, down from $517000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $1.9 million in Q3 2024 to a low of $6000.0 in Q1 2024.
• The 3-year median for Other financing activities is $378000.0 (2026), against an average of $744428.6.
• Peak annual rise in Other financing activities reached 58.1% in 2025, while the deepest fall reached 86.76% in 2025.
• MBX Biosciences' Other financing activities stood at $327000.0 in 2024, then soared by 58.1% to $517000.0 in 2025, then declined by 26.89% to $378000.0 in 2026.
• The last three Other financing activities figures came in at $378000.0 (Q1 2026), $517000.0 (Q4 2025), and $254000.0 (Q3 2025), per Business Quant data.